Biocom Systems, Inc. Japanese / English
Site map
SKIN-CAD Overview > Presentations


The following R&Ds include SKIN-CAD simulations.

Articles
  1. Hikima, T.; Kaneda, N.; Matsuo, K.; Tojo, K. Prediction of percutaneous absorption in human using three-dimensional human cultured epidermis LabCyte EPI-MODEL, Biol. Pharm. Bull. 2012, in press. New
  2. Nakamura, A.; Mori, D.; Tojo, K. Evaluation of the predicted time-concentration profile of serum tulobuterol in human after transdermal application. Chem. Pharm. Bull. 2012, in press. New
  3. Olatunji, O.; Das, D.B.; Nassehi, V. Modelling transdermal drug delivery using microneedles: Effect of geometry on drug transport behaviour. J. Pharm. Sci. 2012, 101(1), 164-175. New
  4. Tominaga, K.; Tojo, K. Effect of environmental temperature on transdermal drug penetration. Biol. Pharm. Bull. 2010, 33(12), 1983-1987.
  5. Al-Qallaf, B.; Mori, D.; Olatunji, L.; Das, D.B.; Cui, Z. Transdermal drug delivery by microneedles: Does skin metabolism matter? Int. J. Chem. React. Eng. 2009, 7, A69.
  6. Al-Qallaf, B.; Das, D.B.; Davidson, A. Transdermal drug delivery by coated microneedles: geometry effects on drug concentration in blood. Asia-Pacific J. Chem. Eng. 2009, 4(6), 845-857.
  7. Hikima, T.; Ohsumi, S.; Shirouzu, K.; Tojo, K. Mechanisms of synergistic skin penetration by sonophoresis and iontophoresis. Biol. Pharm. Bull. 2009, 32(5), 905-909.
  8. Al-Qallaf, B.; Das, D.B. Optimization of square microneedle arrays for increasing drug permeability in skin. Chem. Eng. Sci. 2008, 63, 2523-2535.
  9. Al-Qallaf, B.; Das, D.B.; Mori, D.; Cui, Z. Modelling transdermal delivery of high molecular weight drugs from microneedle systems. Phil. Trans. R. Soc. A 2007, 365(1861), 2951–2967.
  10. Tojo, K.; Hikima, T. Bioequivalence of marketed transdermal delivery systems for tulobuterol. Biol. Pharm. Bull. 2007, 30(8), 1576-1579.
  11. Kimura, C.; Tojo, K. Development of a stick-type transdermal eyelid delivery system of ketotifen fumarate for ophthalmic diseases. Chem. Pharm. Bull. 2007, 55(7), 1002-1005.
  12. Isowaki, A.; Ohtori, A.; Matsuo, Y.; Tojo, K. Drug delivery to the eye with a transdermal therapeutic system. Biol. Pharm. Bull. 2003, 26(1), 69-72.
  13. Mori, D.; Kawamata, H.; Tojo, K. Drug concentration - time profile in the plasma following the dissolution-type transdermal delivery. J. Chem. Eng. Japan 2003, 36(1), 45-48.
  14. Kawamata, H.; Tojo, K. Prediction of plasma concentration of GTS-21 in hairless rats following monolithic transdermal delivery. Biol. Pharm. Bull. 2002, 25(3), 342-345.
Conferences
  1. Olatunji, O.; Das, D.B.; Al-Qallaf, B. Simulation based optimization of microneedle geometry to improve drug permeability in skin. Proceedings of the 7th International Industrial Simulation Conference’ 2009 (ISC’2009), Loughborough, UK, June 1-3, 2009.
  2. Kimura, C.; Tojo, K. Stick-type transdermal delivery system for ocular diseases. Proceedings of the 2007 AAPS Annual Meeting and Exposition, San Diego, CA, November 10-15, 2007.
  3. Mori, D.; Tojo, K. SKIN-CAD®: Pharmacokinetic model for transdermal drug delivery. Proceedings of the 2006 AIChE Annual Meeting, San Francisco, CA, November 12-17, 2006.
  4. Mori, D.; Tojo, K. In silico evaluation for skin pharmacokinetics. Proceedings of the 29th Annual Meeting of Controlled Release Society, Seoul, Korea, July 20-25, 2002.
Patents
  1. Yutoku Pharmaceutical Industries Co., Ltd. Riluzole-containing transdermal patch. WO/2010/113225.
  2. Tojo, K.; Kimura, C. Solid ophthalmic drug for external use. EP1852106.
  3. Nitto Denko Corporation; Toa Eiyo Ltd. Device for the transdermal administration of bisoprolol. WO/2008/108424, EP2119437; Percutaneous administration device of bisoprolol. US 2010/0098747.
  4. Hisamitsu Pharmaceutical Co., Inc. Patch. US 2009/0012181, US 2010/0227932, EP1847264.
  5. Nitto Denko Corporation Adhesive preparation containing fentanyl. US 2006/0034900, EP1625845.
  6. Hisamitsu Pharmaceutical Co., Inc. Percutaneous absorption preparations. WO/2003/032960, US 2004/0258741, EP1437130.





For customers

Please contact us if you have any questions and comments.